PL3850113T3 - Markery przydatne w strategiach wzbogacania przy leczeniu choroby zwyrodnieniowej stawów - Google Patents

Markery przydatne w strategiach wzbogacania przy leczeniu choroby zwyrodnieniowej stawów

Info

Publication number
PL3850113T3
PL3850113T3 PL19762829.0T PL19762829T PL3850113T3 PL 3850113 T3 PL3850113 T3 PL 3850113T3 PL 19762829 T PL19762829 T PL 19762829T PL 3850113 T3 PL3850113 T3 PL 3850113T3
Authority
PL
Poland
Prior art keywords
ostearthritis
treatment
markers useful
enrichment strategies
enrichment
Prior art date
Application number
PL19762829.0T
Other languages
English (en)
Inventor
Christoph H. Ladel
Hans Guehring
Anne-Christine BAY-JENSEN
Morten Karsdal
Per Qvist
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL3850113T3 publication Critical patent/PL3850113T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1841Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1875Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/23Calcitonins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
PL19762829.0T 2018-09-10 2019-09-09 Markery przydatne w strategiach wzbogacania przy leczeniu choroby zwyrodnieniowej stawów PL3850113T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18193351 2018-09-10
PCT/EP2019/074003 WO2020053155A1 (en) 2018-09-10 2019-09-09 Markers useful in enrichment strategies for the treatment of osteoarthritis

Publications (1)

Publication Number Publication Date
PL3850113T3 true PL3850113T3 (pl) 2024-09-02

Family

ID=63685561

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19762829.0T PL3850113T3 (pl) 2018-09-10 2019-09-09 Markery przydatne w strategiach wzbogacania przy leczeniu choroby zwyrodnieniowej stawów

Country Status (18)

Country Link
US (1) US12383603B2 (pl)
EP (1) EP3850113B1 (pl)
JP (2) JP7568614B2 (pl)
KR (1) KR20210057764A (pl)
CN (1) CN113286896A (pl)
AU (1) AU2019337786B2 (pl)
BR (1) BR112021004356A2 (pl)
CA (1) CA3111671A1 (pl)
DK (1) DK3850113T3 (pl)
ES (1) ES2980597T3 (pl)
FI (1) FI3850113T3 (pl)
HR (1) HRP20240665T1 (pl)
HU (1) HUE067058T2 (pl)
IL (1) IL281333B2 (pl)
MX (1) MX2021002803A (pl)
PL (1) PL3850113T3 (pl)
SG (1) SG11202102160VA (pl)
WO (1) WO2020053155A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3688468T3 (pl) 2017-09-29 2022-07-18 Merck Patent Gmbh Biomarkery stanu zapalnego do przewidywania odpowiedzi na związek fgf-18
DK3687558T3 (da) 2017-09-29 2022-06-20 Merck Patent Gmbh Metaboliske biomarkører til forudsigelse af modtageligheden på fgf-18 forbindelse
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial
CN113425855B (zh) * 2021-06-28 2023-11-07 深圳瑞吉生物科技有限公司 一种mRNA剂型的骨关节炎药物制剂及其制备方法和应用
GB2630642A (en) * 2023-06-02 2024-12-04 Mako Surgical Corp Image processing method

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837841A (en) 1996-10-11 1998-11-17 Incyte Pharmaceuticals, Inc. Human Reg protein
IL129379A (en) 1996-10-16 2008-12-29 Zymogenetics Inc Fibroblast growth factor homologues
US20040136970A1 (en) 2002-10-07 2004-07-15 Ellsworth Jeff L. Methods for administering FGF18
EP1558932A2 (en) 2002-11-08 2005-08-03 Barnes-Jewish Hospital Uncoupled collagen synthesis and degradation assays
PL1828239T3 (pl) 2004-12-10 2012-01-31 Zymogenetics Inc Produkcja FGF18 w organizmach prokariotycznych
US8224579B2 (en) 2005-06-17 2012-07-17 The Brigham And Women's Hospital, Inc. Method of diagnosing osteoarthritis
CA2658511C (en) 2006-08-25 2019-02-19 Ares Trading S.A. Use of fgf-18 compound to treat cartilage disorders
JP2009257842A (ja) 2008-04-14 2009-11-05 Ttc:Kk 変形性関節症の検査方法及び診断用キット
EP2283156B1 (en) * 2008-05-02 2015-11-11 Interleukin Genetics, Inc. Detecting genetic predisposition to osteoarthritis associated conditions
US20090299769A1 (en) * 2008-05-29 2009-12-03 Nordic Bioscience Imaging A/S Prognostic osteoarthritis biomarkers
US20120115137A1 (en) 2010-08-31 2012-05-10 Kornman Kenneth S Methods of Predicting Osteoarthritis
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Fgf-18之凍乾調配物
CN104736723B (zh) 2012-08-06 2017-10-31 默克专利有限公司 用于预测对fgf‑18化合物的响应性的遗传标记
PL2880181T3 (pl) 2012-08-06 2019-03-29 Merck Patent Gmbh Biomarkery prognostyczne w zaburzeniach chrząstki
CA2931978A1 (en) 2013-12-02 2015-06-11 Abbvie Inc. Compositions and methods for treating osteoarthritis
BR112016014717B1 (pt) 2013-12-24 2020-12-01 Ares Trading S.A. sistema de gelificação de dois componentes, método para produção de um hidrogel homogêneo, e artigo de produção
JP6791754B2 (ja) 2013-12-24 2020-11-25 アレス トレーディング ソシエテ アノニム キシログルカンゲル中のfgf−18製剤
EP3107559B1 (en) 2014-02-20 2018-07-11 Merck Patent GmbH Fgf-18 compound dosing regimen
BR112016018681B1 (pt) 2014-02-20 2021-01-05 Merck Patent Gmbh sistema de distribuição de substâncias que compreende pelo menos um material polimérico formador de uma matriz e um fármaco anabólico, processo de produção do mesmo e artigo de manufatura
AU2015220781B2 (en) 2014-02-20 2018-05-24 Merck Patent Gmbh FGF-18 in graft transplantation and tissue engineering procedures
WO2016120387A1 (en) 2015-01-29 2016-08-04 Ares Trading S.A. Immunoassays for high positively charged proteins
NZ742200A (en) 2015-11-06 2023-01-27 Samumed Llc Treatment of osteoarthritis
US9983214B2 (en) 2016-04-15 2018-05-29 Esm Technologies, Llc Method for evaluating articular joint therapeutics
DK3687558T3 (da) 2017-09-29 2022-06-20 Merck Patent Gmbh Metaboliske biomarkører til forudsigelse af modtageligheden på fgf-18 forbindelse
PL3688468T3 (pl) 2017-09-29 2022-07-18 Merck Patent Gmbh Biomarkery stanu zapalnego do przewidywania odpowiedzi na związek fgf-18
AU2019222715B2 (en) * 2018-02-14 2021-09-16 Dolby Laboratories Licensing Corporation Image reshaping in video coding using rate distortion optimization
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial

Also Published As

Publication number Publication date
FI3850113T3 (fi) 2024-07-03
WO2020053155A1 (en) 2020-03-19
US12383603B2 (en) 2025-08-12
CN113286896A (zh) 2021-08-20
ES2980597T3 (es) 2024-10-02
CA3111671A1 (en) 2020-03-19
EP3850113A1 (en) 2021-07-21
AU2019337786A1 (en) 2021-04-15
DK3850113T3 (da) 2024-06-10
JP7568614B2 (ja) 2024-10-16
JP2025000980A (ja) 2025-01-07
SG11202102160VA (en) 2021-04-29
IL281333A (en) 2021-04-29
HUE067058T2 (hu) 2024-09-28
IL281333B2 (en) 2025-11-01
MX2021002803A (es) 2021-07-16
IL281333B1 (en) 2025-07-01
BR112021004356A2 (pt) 2021-08-03
AU2019337786B2 (en) 2026-02-05
EP3850113B1 (en) 2024-04-03
HRP20240665T1 (hr) 2024-08-16
JP2022511305A (ja) 2022-01-31
KR20210057764A (ko) 2021-05-21
US20220047674A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
IL285178A (en) Compounds and uses thereof
HUS2500039I1 (hu) Elafibranor primer biliáris cirrózis kezelésében történõ alkalmazásra
IL280536A (en) Muscle targeting complexes and uses thereof
IL279965A (en) Fusion constructs and methods of using thereof
DK3743053T3 (da) Anvendelse af cannabinoider i behandling af epilepsi
IL282998A (en) Pyridazinone compounds and uses thereof
DK3497094T3 (da) Tlr7/8-antagonister og anvendelser deraf
IL278122B1 (en) Pteridinone compounds and uses thereof
MA45192A (fr) Traitement d'association
MA46716A (fr) Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
EP3497086A4 (en) AMINOPYRIMIDINE SSAO INHIBITORS
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
IL248299B (en) A method and kit for determining the tissue or cell origin of dna
EP3430731A4 (en) IUGW ARCHITECTURE
DK3655401T3 (da) Tlr7/8-antagonister og anvendelser deraf
DK3578547T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
DK3429571T3 (da) Kombinationer af lsd1-hæmmere til anvendelse til behandling af neoplastiske sygdomme
DK4014976T3 (da) Aprocitentan til anvendelse i behandlingen af hypertension og relaterede sygdomme i kombination med valsartan
PL3850113T3 (pl) Markery przydatne w strategiach wzbogacania przy leczeniu choroby zwyrodnieniowej stawów
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
MA49006A (fr) Inhibiteurs d'ip6k
DK3532059T3 (da) Kombinationsterapi med bromdomæne- og ekstraterminal proteinhæmmer
DK3576738T3 (da) Gaboxadolmonohydrat i behandling af tinnitus